Rossi Michael A.

SEC source: 0000921895-23-000013 · form412799ros_01032023.xml · nonDerivative · entry 3

Rossi Michael A. · CIK 0001783869 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 260,540

F5 · shares: The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with a performance restricted stock unit award previously granted to the Reporting Person that vested in part on December 29, 2022.

F6 · balance_after: Includes (a) the shares and awards described in footnote (2) above, less (b) the disposition of shares reported in footnotes (3) and (5) above.

SEC source: 0000921895-23-000013 · form412799ros_01032023.xml · nonDerivative · entry 2

Rossi Michael A. · CIK 0001783869 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 263,575

F3 · shares: The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with a restricted stock unit award previously granted to the Reporting Person that vested in part on December 29, 2022.

F4 · balance_after: Includes (a) the shares and awards described in footnote (2) above, less (b) the disposition of shares reported in footnote (3) above.

SEC source: 0000921895-23-000013 · form412799ros_01032023.xml · nonDerivative · entry 1

Rossi Michael A. · CIK 0001783869 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 267,338

F1 · shares: The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with a restricted stock unit award previously granted to the Reporting Person that vested in part on December 29, 2022.

F2 · balance_after: Include (a) 20,681 restricted stock units that will vest in two equal installments on December 29, 2023 and 2024, (b) 21,545 restricted stock units that will vest on June 11, 2023, (c) 12,821 restricted stock units that will vest on December 29, 2023, (d) 65,592 restricted stock units with performance based vesting conditions, (e) 10,772 restricted stock units that will vest on December 29, 2023, and (f) 135,927 shares of common stock beneficially owned by the Reporting Person.

SEC source: 0000921895-22-002258 · form412799001_07202022.xml · nonDerivative · entry 1

Rossi Michael A. · CIK 0001783869 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 270,500

F1 · shares: The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with a restricted stock unit award previously granted to the Reporting Person that fully vested on July 18, 2022.

F2 · balance_after: Include (a) 31,021 restricted stock units that will vest in three equal installments on December 29, 2022, 2023 and 2024, (b) 21,545 remaining restricted stock units that will vest on June 11, 2023, (c) 25,641 restricted stock units that will vest in two equal installments on December 29, 2022 and 2023, (d) 65,592 restricted stock units with performance based vesting conditions, (e) 21,545 remaining restricted stock units that will vest on December 29, 2022 and 2023, and (f) 105,156 shares of common stock beneficially owned by the Reporting Person.

SEC source: 0000921895-22-001987 · form412799001ros_06142022.xml · nonDerivative · entry 1

Rossi Michael A. · CIK 0001783869 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 277,508

F1 · shares: The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with a performance restricted stock unit award previously granted to the Reporting Person that vested in part on June 11, 2022.

F2 · balance_after: Include (a) 31,021 restricted stock units that will vest in three equal installments on December 29, 2022, 2023 and 2024, (b) 21,545 remaining restricted stock units that will vest on June 11, 2023, (c) 25,641 restricted stock units that will vest in two equal installments on December 29, 2022 and 2023, (d) 65,592 restricted stock units with performance based vesting conditions, (e) 23,878 remaining restricted stock units that will vest on July 18, 2022, (f) 21,545 remaining restricted stock units that will vest on December 29, 2022 and 2023, and (g) 88,286 shares of common stock beneficially owned by the Reporting Person.

SEC source: 0001193805-22-000420 · e621404_4-michael.xml · nonDerivative · entry 2

Rossi Michael A. · CIK 0001783869 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 283,833

F3 · shares: Represents an award of 28,716 restricted stock units with performance based vesting conditions. These restricted stock units will vest upon the achievement of a relative total shareholder return of the Issuer's common stock during the period from March 1, 2022 to the earlier of (i) December 31, 2024, and (ii) the date of a change of control (the "Measurement Period"), measured relative to the Russell 2000 index and based on the 20-day trading average beginning on the first day of the Measurement Period and ending on the last day of the Measurement Period, subject to the terms set forth in an award agreement between the Issuer and the Reporting Person. The target number of these restricted stock units that may be earned is reported above; the maximum amount is 150% of the number reported.

F4 · balance_after: Includes (a) the shares and awards described in footnote (2) above, and (b) the award described in footnote (3) above.

SEC source: 0001193805-22-000420 · e621404_4-michael.xml · nonDerivative · entry 1

Rossi Michael A. · CIK 0001783869 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 255,117

F1 · shares: Represents an award of 31,021 restricted stock units that will vest in three equal installments on December 29, 2022, 2023 and 2024, subject to the terms set forth in an award agreement between the Issuer and the Reporting Person.

F2 · balance_after: Includes (a) the award described in footnote (1) above, (b) 43,092 remaining restricted stock units that will vest on June 11, 2022 and 2023, (c) 25,641 restricted stock units that will vest in two equal installments on December 29, 2022 and 2023, (d) 36,876 restricted stock units with performance based vesting conditions, (e) 23,878 remaining restricted stock units that will vest on July 18, 2022, (f) 21,545 remaining restricted stock units that will vest on December 29, 2022 and 2023, and (g) 73,064 shares of common stock beneficially owned by the Reporting Person.

SEC source: 0000921895-22-000035 · form412799ros_01032022.xml · nonDerivative · entry 2

Rossi Michael A. · CIK 0001783869 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 224,096

F3 · shares: The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with a performance restricted stock unit award previously granted to the Reporting Person that vested in part on December 29, 2021.

F4 · balance_after: Includes (a) the shares and awards described in footnote (2) above, less (b) the disposition of shares reported in footnote (3) above.

SEC source: 0000921895-22-000035 · form412799ros_01032022.xml · nonDerivative · entry 1

Rossi Michael A. · CIK 0001783869 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 227,859

F1 · shares: The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with a performance restricted stock unit award previously granted to the Reporting Person that vested in part on December 29, 2021.

F2 · balance_after: Includes (a) 43,092 remaining restricted stock units that will vest on June 11, 2022 and 2023, (b) 25,641 restricted stock units that will vest in two equal installments on December 29, 2022 and 2023, (c) 36,876 restricted stock units with performance based vesting conditions, (d) 23,878 remaining restricted stock units that will vest on July 18, 2022, (e) 21,545 remaining restricted stock units that will vest on December 29, 2022 and 2023, and (f) 76,827 shares of common stock beneficially owned by the Reporting Person.

SEC source: 0000921895-21-001884 · form412799001_07202021.xml · nonDerivative · entry 1

Rossi Michael A. · CIK 0001783869 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 231,022

F1 · shares: The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with a performance restricted stock unit award previously granted to the Reporting Person that vested in part on July 18, 2021.

F2 · balance_after: Includes (a) 43,092 remaining restricted stock units that will vest on June 11, 2022 and 2023, (b) 38,462 restricted stock units that will vest in three equal installments on December 31, 2021, 2022 and 2023, (c) 36,876 restricted stock units with performance based vesting conditions, (d) 23,878 remaining restricted stock units that will vest on July 18, 2022, (e) 32,319 remaining restricted stock units that will vest on December 31, 2021, 2022 and 2023, and (f) 56,395 shares of common stock beneficially owned by the Reporting Person.

SEC source: 0000921895-21-001649 · form412799ros_06152021.xml · nonDerivative · entry 2

Rossi Michael A. · CIK 0001783869 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 237,988

F3 · shares: The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with the performance restricted stock unit award previously granted to the Reporting Person that vested in part on June 11, 2021.

F4 · balance_after: Includes (a) the shares and awards described in footnote (2) above, less (b) the disposition of shares reported in footnote (3) above.

SEC source: 0000921895-21-001649 · form412799ros_06152021.xml · nonDerivative · entry 1

Rossi Michael A. · CIK 0001783869 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 244,160

F1 · shares: On June 11, 2020, the Reporting Person was granted an award of 43,092 restricted stock units with performance based vesting conditions, which vest in equal installments on June 11, 2021, 2022 and 2023, and are linked to the achievement of a relative total shareholder return of the Issuer's common stock from June 11, 2020 to the earlier of (i) June 11, 2021 or (ii) upon a change of control (measured relative to the Nasdaq Biotechnology index). The target number of the restricted stock units that may be earned was reported on the date of grant; the maximum amount is 150% of the number then reported. As a result of the Issuer's performance based on such performance targets, the Reporting Person earned 150% of the target amount, subject to continuation of employment through the remaining vesting dates. Accordingly, the reported transaction reflects the acquisition of 21,546 additional performance restricted stock units earned above the target grant.

F2 · balance_after: Includes (a) 43,092 remaining restricted stock units that will vest on June 11, 2022 and 2023, (b) 38,462 restricted stock units that will vest in three equal installments on December 31, 2021, 2022 and 2023, (c) 36,876 restricted stock units with performance based vesting conditions, (d) 47,753 remaining restricted stock units that will vest on July 18, 2021 and 2022, (e) 32,319 remaining restricted stock units that will vest on December 31, 2021, 2022 and 2023, and (f) 45,658 shares of common stock beneficially owned by the Reporting Person.

SEC source: 0000921895-21-000617 · form412799ros_03032021.xml · nonDerivative · entry 2

Rossi Michael A. · CIK 0001783869 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 222,614

F3 · shares: Represents an award of 36,876 restricted stock units with performance based vesting conditions. These restricted stock units will vest upon the achievement of a relative total shareholder return of the Issuer's common stock during the period from March 1, 2021 to the earlier of (i) December 31, 2023, and (ii) the date of a change of control (the "Measurement Period"), measured relative to the Russell 2000 index and based on the 20-day trading average beginning on the first day of the Measurement Period and ending on the last day of the Measurement Period, subject to the terms set forth in an award agreement between the Issuer and the Reporting Person. The target number of these restricted stock units that may be earned is reported above; the maximum amount is 150% of the number reported.

F4 · balance_after: Includes (a) the shares and awards described in footnote (2) above, and (b) the award described in footnote (3) above.

SEC source: 0000921895-21-000617 · form412799ros_03032021.xml · nonDerivative · entry 1

Rossi Michael A. · CIK 0001783869 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 185,738

F1 · shares: Represents an award of 38,462 restricted stock units that will vest in three equal installments on December 31, 2021, 2022 and 2023, subject to the terms set forth in an award agreement between the Issuer and the Reporting Person.

F2 · balance_after: Includes (a) the award described in footnote (1) above, (b) 47,753 remaining restricted stock units that will vest on July 18, 2021 and 2022, (c) 32,319 remaining restricted stock units that will vest on December 31, 2021, 2022 and 2023, (d) 43,092 restricted stock units with performance based vesting conditions tied to relative total shareholder return that will vest on June 11, 2021, 2022 and 2023, and (e) 24,112 shares of common stock beneficially owned by the Reporting Person.

SEC source: 0000921895-21-000029 · form412799ros_01052021.xml · nonDerivative · entry 1

Rossi Michael A. · CIK 0001783869 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 147,276

F1 · shares: The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with a restricted stock unit award previously granted to the Reporting Person which vested in part on December 31, 2020.

F2 · balance_after: Includes (a) 47,753 remaining restricted stock units that will vest on July 18, 2021 and 2022; (b) 32,319 remaining restricted stock units that will vest on December 31, 2021, 2022 and 2023; (c) 43,092 restricted stock units with performance based vesting conditions tied to relative total shareholder return that will vest on June 11, 2021, 2022 and 2023; and (d) 24,112 shares of common stock beneficially owned by the Reporting Person.

SEC source: 0001209191-20-043251 · doc4.xml · nonDerivative · entry 2

Rossi Michael A. · CIK 0001783869 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 151,020

F3 · shares: The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with the performance restricted stock unit award previously granted to the Reporting Person that vested in part on July 18, 2020.

F4 · balance_after: Includes (a) the shares and awards described in footnote (2) above, less (b) the disposition of shares reported in footnote (3) above.

SEC source: 0001209191-20-043251 · doc4.xml · nonDerivative · entry 1

Rossi Michael A. · CIK 0001783869 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 157,814

F1 · shares: On July 18, 2019, the Reporting Person was granted an award of 47,753 restricted stock units with performance based vesting conditions based on the achievement of a relative total shareholder return of the Issuer's common stock from July 18, 2019 to the earlier of (i) July 18, 2020 or (ii) upon a change of control (measured relative to the NASDAQ Biotechnology index). The target number of the restricted stock units that may be earned was reported on the date of grant; the maximum amount is 150% of the number then reported. As a result of the Issuer's performance based on such performance targets, the Reporting Person earned 150% of the target amount, subject to continuation of employment through the remaining vesting dates. Accordingly, the reported transaction reflects the acquisition of 23,877 additional performance restricted stock units earned above the target grant.

F2 · balance_after: Includes (a) 47,753 remaining restricted stock units that will vest on July 18, 2021 and 2022, (b) 43,092 restricted stock units that will vest on December 31, 2020, 2021, 2022 and 2023; (c) 43,092 restricted stock units with performance based vesting conditions tied to relative total shareholder return that will vest on June 11, 2021, 2022 and 2023; and (d) 23,877 shares of common stock beneficially owned by the Reporting Person.

SEC source: 0001209191-20-036761 · doc4.xml · derivative · entry 3

Rossi Michael A. · CIK 0001783869 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,896

Underlying: Common Stock · 92,896 shares

Expires 2027-06-11

F5 · derivative.exercise_date: The options vest in four equal installments on December 31, 2020, 2021, 2022 and 2023.

SEC source: 0001209191-20-036761 · doc4.xml · nonDerivative · entry 2

Rossi Michael A. · CIK 0001783869 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 133,937

F3 · shares: Represents an award of 43,092 restricted stock units with performance based vesting conditions. These restricted stock units will vest in equal installments on June 11, 2021, 2022 and 2023, and are linked to the achievement of a relative total shareholder return of the Issuer's common stock from June 11, 2020 to the earlier of (i) June 11, 2021 or (ii) upon a change of control (measured relative to the NASDAQ Biotechnology index and based on the 20-day trading average price before each such date). The target number of these restricted stock units that may be earned is reported above; the maximum amount is 150% of the number reported.

F4 · balance_after: Includes (a) the shares and awards described in footnote (2) above, and (b) the award described in footnote (3) above.

SEC source: 0001209191-20-036761 · doc4.xml · nonDerivative · entry 1

Rossi Michael A. · CIK 0001783869 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,845

F1 · shares: Represents an award of 43,092 restricted stock units that will vest in four equal installments on December 31, 2020, 2021, 2022 and 2023.

F2 · balance_after: Includes (a) the award described in footnote (1) above, and (b) 47,753 restricted stock units with performance based vesting conditions tied to relative total shareholder return.

SEC source: 0001209191-19-043709 · doc4.xml · derivative · entry 2

Rossi Michael A. · CIK 0001783869 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 111,842

Underlying: Common Stock, par value $0.01 per share · 111,842 shares

Expires 2029-07-18

F3 · derivative.exercise_date: The options vest in four equal annual installments on July 18, 2020, 2021, 2022 and 2023.

SEC source: 0001209191-19-043709 · doc4.xml · nonDerivative · entry 1

Rossi Michael A. · CIK 0001783869 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,753

F1 · shares: Represents a deferred stock award of 47,753 restricted stock units with performance based vesting conditions. These restricted stock units shall vest in equal installments on July 18, 2020, 2021 and 2022, and are linked to the achievement of a relative total shareholder return of the Issuer's common stock from July 18, 2019 to the earlier of (i) July 18, 2020 or (ii) upon a change of control (measured relative to the NASDAQ Biotechnology index and based on the 20-day trading average price before each such date). The target number of these restricted stock units that may be earned is reported above; the maximum amount is 150% of the number reported.

F2 · balance_after: Includes the award described in footnote (1) above.